In 2002, the recombinant form of urate oxidase or rasburicase was approved by the Food and Drug Administration [13,14] following the successful results published by Goldman et al. [15] and Pui et al. [16] Based on the highly successful results on the management of hyperuricemia, intravenous rasburicase was licenced at a dose of 0.2 mg/kg/day for five days consecutively with the first dose given prior to the commencement of chemotherapy. The gene discussed is UOX; the disease is hyperuricemia.